Fighting Cancer Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Introducing the OraMark™ Laboratory Developed Test for the U.S!

Learn More about OraMark™
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • vb-400x210

    Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer

    FORT LAUDERDALE, Fla. and SEATTLE, AHNS Conference – July 13, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced a presentation of data related to…more

  • miami-herald_logo2

    Life sciences company taking oral cancer detection products to market

    Vigilant Biosciences is developing products for the early detection and intervention of cancer. On Monday, the Fort Lauderdale life sciences company announced it closed a $5 million round of financing, bringing its total amount of funding raised to date to…more

  • sunsentinel

    Fort Lauderdale-based Vigilant Biosciences raises $5 million for oral cancer detection products

    Fort Lauderdale startup Vigilant Biosciences has raised $5 million from investors, bringing its total amount raised to $12.5 million to date, the company said Monday. The money will be used for commercial development of the company’s OncAlert oral cancer detection…more

  • MedCityNews_Logo

    Vigilant Biosciences raises $10.5M in Series B round

    Vigilant Biosciences, an oral cancer testing company, announced that it has raised a total of $10.5 million in Series B financing. The second phase of the Series B round brought in $5 million and investors in this phase included White…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×